🟢 Biovie is trading 6.97% up in pre-market amid speculative volatility

Biovie is trading 6.97% up at $1.87, with the move appearing to reflect speculative volatility and broader pre-market risk appetite.

• Rebounding after a 14.63% decline to $1.75 on September 15.
• Phase 2 ADDRESS-LC failed to reach statistical significance across the overall 203-patient population; certain higher-severity subgroups improved and safety remained favorable.
• No new company-specific catalyst was identified on September 16.